Stenotrophomonas Bacteremia Antibiotic Susceptibility and Prognostic Determinants: Mayo Clinic 10-Year Experience
Ahmed M Hamdi1, Madiha Fida1, Omar M Abu Saleh1
1Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Background:
Stenotrophomonas maltophilia is a gram-negative, opportunistic infection that is usually hospital-acquired and associated with high morbidity and mortality. The reported increase in S. maltophilia infections is presumed to be due to an increase in the population at risk.
Methods:
We retrospectively reviewed 10-year data for S. maltophilia bacteremia in hospitalized adults at our institution to determine the population at risk, sources of infection, common complications, antimicrobial susceptibility profiles, and clinical outcome trends over the past decade.
Results:
Among the 98 patients analyzed, the most common source of infection was catheter-related (62, 63.3%). Most isolates (61, 65%) were resistant to ceftazidime; fewer were resistant to trimethoprim-sulfamethoxazole (TMP-SMX; 2, 2.1%) and levofloxacin (22, 23.4%). All-cause in-hospital mortality was 29.6% (29 patients). The highest mortality, 53.8%, was observed in pulmonary sources of bacteremia.
Conclusions:
Although TMP-SMX continues to have reliable activity in our cohort, we noted resistance to TMP-SMX in patients with recent TMP-SMX exposure, including a case with developing resistance to TMP-SMX while on therapy.
Insights
Trimethoprim-sulfamethoxazole (TMP-SMX) remains effective against Stenotrophomonas maltophilia bacteremia, though resistance emerged in patients with prior TMP-SMX exposure. Catheter-related infections were most common, with high mortality observed in pulmonary cases.
Area of Science:
- Medical Microbiology
- Infectious Diseases
- Clinical Medicine
Background:
- Stenotrophomonas maltophilia is an opportunistic gram-negative bacterium causing severe hospital-acquired infections.
- Increasing incidence of S. maltophilia infections is linked to a growing at-risk patient population.
Purpose of the Study:
- To analyze a decade of S. maltophilia bacteremia data in hospitalized adults.
- To identify at-risk populations, infection sources, complications, and antimicrobial resistance trends.
Main Methods:
- Retrospective review of 10-year patient data.
- Analysis of S. maltophilia bacteremia cases in hospitalized adults.
- Assessment of antimicrobial susceptibility profiles and clinical outcomes.
Main Results:
- Catheter-related infections were the most frequent source (63.3%).
- High resistance rates were observed for ceftazidime (65%), with lower rates for trimethoprim-sulfamethoxazole (TMP-SMX; 2.1%) and levofloxacin (23.4%).
- Overall in-hospital mortality was 29.6%, with pulmonary sources showing the highest mortality (53.8%).
Conclusions:
- TMP-SMX demonstrated reliable activity in the studied cohort.
- Emergence of TMP-SMX resistance was noted in patients with recent exposure, including during therapy.
- Catheter-related bacteremia and pulmonary infections represent significant challenges in managing S. maltophilia.
Related Concept Videos
Antibiotic Selection
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Acute Pyelonephritis II: Diagnostic Studies and Management
Urine Studies II: Urine Culture and Sensitivity Test
Mechanism of Antibiotic Resistance in MRSA
Clinical Significance of Antibiotic Resistance


